Panagin Pharmaceuticals Inc.

Panagin Pharmaceuticals Inc., a privately-held biotech company, specializes in the discovery, research, development and commercialization of saponin based anti-cancer drugs. Panagin's proprietary new drug candidates show strong anti-cancer properties against various advanced, metastatic, multi-drug resistant cancers. Panagin's research and clinical programs focus on life-threatening diseases, such as lung cancer, pancreatic cancer, and brain metastases from various original sites.
Panagin's goal is to provide pharmaceutical treatment for cancers using saponin technology. Its growth strategy is to develop one or more of its portfolio candidates to Phase II clinical trials for cancer indications that currently do not have effective treatment.
Panagin has completed pre-IND communications with US FDA. In 2004, the Company is preparing to file IND and conduct Phase I clinical studies of PBD-2131B (oral) for the treatment of lung cancer and other solid tumours. In 2005, Panagin plans to advance another drug candidate PAM-200 to the clinic for the treatment of brain metastases from original lung cancer.
Pandimex™ (PBD-2131B injection), has received conditional market approval in China for the treatment of advanced cancers of lung, breast, pancreas, stomach and colon-rectum. Pandimex™ can be used as a single agent and combination agent with paclitaxel. A Panagin-controlled joint venture is formed to market Pandimex™, and to upgrade its regulatory status to a full NDA approval.

Contact Details: Unit 110-116, 11800 River Road Richmond British Columbia V6X 1Z7 Canada Tel: 604.303.9988 Fax: 604.303.9926 Email: info@panagin.com WWW: www.panagin.com/

Loading...

BioNews Results for Panagin Pharmaceuticals Inc.:
Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference	Pharma Live:  Nov 23 2009 2:24AM Matching: pharmaceuticals inc
Analyst Choice Brings New Analysis on Level 3 Communications Inc., Arris Group Inc., Virgin Media Inc., The South Financial Group Inc., Wynn Resorts Limited and AMAG Pharmaceuticals Inc.	Individual.com:  Nov 21 2009 6:41AM Matching: pharmaceuticals inc
Ironwood Pharmaceuticals Files Registration Statement for Initial Public Offering	RBC Dain Rauscher:  Nov 21 2009 12:46AM Matching: pharmaceuticals inc
FDA approves sNDA for pediatric autism drug ABILIFY	News-Medical.Net:  Nov 21 2009 4:57AM Matching: pharmaceuticals inc
Global market for anti-depressants on a decline	News-Medical.Net:  Nov 20 2009 11:09AM Matching: pharmaceuticals inc
Promote your company here: BioNewsCast - Press Release Distribution	→View more Panagin Pharmaceuticals Inc. news.

Panagin Pharmaceuticals Inc. Patents:
US Patent No.	Title
6949523	Aglycon dammarane sapogenins, their use as anti-cancer agents, and a process for producing same
6888014	Dammarane sapogenins, their use as anti-cancer agents, and a process for producing same

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 864 times since April 2007, the link to the organisation's website has been followed 122 times

Recent Search Terms used to find this page: panagini | panagin | panagin | panagin pharmaceuticals | panagin | PanaGin Pharmaceuticals PAM-120 | panagin | panagin | panagin | panagin | .

Search for more companies in Richmond

Search for more companies in British Columbia

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Panagin Pharmaceuticals Inc.